IVT CUTTING BALLOON IS NOT APPROVABLE BASED ON ANGIOPLASTY EQUIVALENCE DATA, FDA PANEL CONCLUDES; FIRM WILL CONTINUE RESTENOSIS REDUCTION STUDY
This article was originally published in The Gray Sheet
Executive Summary
InterVentional Technologies plans to refocus on demonstrating the potential benefits of the Barath surgical dilatation balloon in reducing coronary artery restenosis as it continues clinical studies of the product. On March 4, FDA's Circulatory System Devices Panel unanimously (8-0) recommended against approval of the device, which is also known as the Cutting Balloon, based on data that attempted to show equivalence to standard balloon angioplasty for coronary artery dilatation.
You may also be interested in...
IVT Launching Cutting Balloon For Highly Resistant Coronary Artery Lesions
InterVentional Technologies' Cutting Balloon microsurgical dilatation catheter system will be promoted to interventional cardiologists as either a primary, secondary or tertiary treatment for highly resistant coronary arterial lesions, the firm says.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.